Allogene Jumps, Compugen Plunges Following Release Of Cancer Meeting Abstracts
May 14, 2020 at 14:08 PM EDT
Jefferies analyst Biren Amin raised his price target on Allogene Therapeutics to $45 from $37, while keeping a Buy rating on the shares.